Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be taken private for a small fraction of the amount at which it was once valued.

By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital Partners at a discount, after a prolonged struggle to survive a cash crunch ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

The sale became more necessary when the FDA denied its third attempt to lasso a priority review voucher (PRV) for its sickle cell disease treatment Lyfgenia, the company said. In October of 2023 ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease and Skysona for cerebral adrenoleukodystrophy. The entire gene therapy field is facing tough ...

LONDON, GREATER LONDON, UNITED KINGDOM, February 11, 2025 /EINPresswire / -- What is the projected growth and market size of the LYFGENIA market? The LYFGENIA market size has observed substantial ...

Its third gene therapy, Lyfgenia (lovotibeglogene autotemcel), is approved for the treatment of sickle cell disease. In a closely competitive race, the therapy secured FDA approval ahead of time ...

The company was founded in 2010 and went public in 2013. In December 2023 it won approval for Lyfgenia, a gene therapy to treat sickle cell disease, its third U.S. drug approval since splitting ...